Baird Maintains an 'Outperform' on Optimer Pharma (OPTR); More than One Way to Say “Superior”? FDA Panel Recommends Fidaxomicin Approval

Baird maintains an 'Outperform' on Optimer Pharmaceuticals (NASDAQ: OPTR), PT $16.

Baird analyst says, "First things first, the panel unanimously recommended approval 13-0, which was expected yet de-risking. Investors may grapple with the second vote, which split 6-7 on the word “recurrence,” but we’d focus more on feedback strongly in favor of a label discussing essentially the same superiority using different words. Our investment thesis never hinged on a single word, so we’d stick with this at least through the approval/labeling event ~5/30/11."

For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $13.80 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• UBS Reiterates Buy Rating on HF Sinclair (DINO)